Literature DB >> 8547669

Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3.

S Buysmann1, F J Bemelman, P T Schellekens, Y van Kooyk, C G Figdor, I J ten Berge.   

Abstract

We investigated the mechanism by which antihuman CD3 monoclonal antibodies of the isotypes IgG2a (eg, OKT3) and IgA (eg, IXA) can induce the rapid disappearance of virtually all circulating T lymphocytes. We hypothesize that upregulation of adhesion molecules on the lymphocyte membrane contributes to this effect. However, this hypothesis is difficult to test, because of the inherent lymphocytopenia and/or shifts in lymphocyte populations between intra and extra-vascular compartments. Therefore, studies in vitro were performed, as well. Analysis of peripheral blood lymphocytes isolated at several times after addition of OKT3 or IXA to whole blood of healthy individuals showed an immediate increase in the proportion of T cells expressing NKI-L16, an activation epitope on CD11a/CD18. Likewise, an increase in CD11b/CD18 expression occurred. In parallel experiments, a transiently increased adhesion of T cells to endothelial cell monolayers was observed. This adhesion could be completely blocked by anti-CD18 or anti-CD11a monoclonal antibodies and only partly by an anti-CD11b antibody. Our data indicate that upregulation of activation epitopes of CD11a/CD18, as well as increased expression of CD11b/CD18 on T lymphocytes, may result in increased adhesion of these cells to intercellular adhesion molecule-1 (ICAM-1) and ICAM-2 on vascular endothelium. This phenomenon may, at least, partly explain the rapidly occurring peripheral lymphocytopenia observed in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8547669

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Drug-induced lymphopenia: focus on CD4+ and CD8+ cells.

Authors:  P Gergely
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

2.  OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.

Authors:  R M van Praag; J M Prins; M T Roos; P T Schellekens; I J Ten Berge; S L Yong; H Schuitemaker; A J Eerenberg; S Jurriaans; F de Wolf; C H Fox; J Goudsmit; F Miedema; J M Lange
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

3.  Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.

Authors:  Kirsten Dettmar; Isabell Seitz-Merwald; Carsten Lindemann; Petra Schroeder; Diane Seimetz; Judith Atz
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

Review 4.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 5.  The safety and side effects of monoclonal antibodies.

Authors:  Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal:  Nat Rev Drug Discov       Date:  2010-03-22       Impact factor: 84.694

6.  Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage.

Authors:  Shihyoung Kim; Rajni Kant Shukla; Eunsoo Kim; Sophie G Cressman; Hannah Yu; Alice Baek; Hyewon Choi; Alan Kim; Amit Sharma; Zhirui Wang; Christene A Huang; John C Reneau; Prosper N Boyaka; Namal P M Liyanage; Sanggu Kim
Journal:  Biomedicines       Date:  2022-05-24

7.  Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.

Authors:  R T Meijer; S Surachno; S L Yong; F J Bemelman; S Florquin; I J M Ten Berge; P T A Schellekens
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

8.  CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.

Authors:  G Molema; J W Tervaert; B J Kroesen; W Helfrich; D K Meijer; L F de Leij
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

Review 9.  CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

Authors:  Lucienne Chatenoud; Herman Waldmann
Journal:  Rev Diabet Stud       Date:  2012-12-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.